Viking Theraputics(Nasdaq: VKTX), a biopharma co. announced the results of a study on monkeys of their SARM(selective androgen receptor modulator). In the primate study, oral vk5211 was administered at doses from 3 to 75 mg/kg for up to 13 weeks. Treated animals demonstrated weight gain of 20 to 47% from their baseline measurements. The animals were shown to maintain their increased weight, maintaining 70% of their gains after a 4 week recovery period.
No opthalmic, electrocardiographic or heart rate changes were observed. And no changes to body chemistry or hematologic factors were observed.
From the Dow Jones newswire. The drug is not yet approved by the FDA.
Apparently there was no exercise program involved. So this drug might be very effective with a weight training program. Of course the big problem is that these companies want a huge price for drugs like this. Probably available only by prescription also.
No opthalmic, electrocardiographic or heart rate changes were observed. And no changes to body chemistry or hematologic factors were observed.
From the Dow Jones newswire. The drug is not yet approved by the FDA.
Apparently there was no exercise program involved. So this drug might be very effective with a weight training program. Of course the big problem is that these companies want a huge price for drugs like this. Probably available only by prescription also.
